Want to see AORT full AI Analyst Report?
AORT Stock Chart & Stats
$25.28
$0.82(3.24%)
At close: 4:00 PM EDT
$25.28
$0.82(3.24%)
Day’s Range― - ―
52-Week Range$19.16 - $48.25
Previous Close$26.62
Volume427.60K
Average Volume (3M)724.70K
Market Cap
$1.41B
Enterprise Value$1.42K
Total Cash (Recent Filing)$77.32M
Total Debt (Recent Filing)$407.97M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Oct 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding48,756,220
10 Day Avg. Volume508,030
30 Day Avg. Volume724,698
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.61
Price to Sales (P/S)4.69
P/FCF Ratio-2.27K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$41.87Price Target Upside65.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$490.26M
Bulls Say, Bears Say
Bulls Say
Platform And Portfolio ExpansionFull ownership of Endospan’s FDA‑approved NEXUS platform and associated pipeline creates a durable competitive advantage in aortic arch solutions. Owning the platform improves cross‑sell, simplifies commercialization, and enlarges the addressable market via multiple follow‑on PMA programs and modular product rollout.
Regulatory Milestone - AMDS PMAAMDS PMA removes prior IRB/HDE limitations, enabling standard commercial adoption across U.S. hospitals. This durable regulatory clearance expands the company’s sales footprint, accelerates account conversion, and supports a material long‑term U.S. revenue opportunity versus constrained, investigational pathways.
Durable Revenue Growth And Strong Gross MarginsConsistent top‑line scaling and high gross margins indicate structurally attractive product economics and market adoption. Stable gross profitability across growth phases supports reinvestment in R&D and commercialization, enabling sustainable margin recovery as integration costs normalize and new products ramp.
Bears Say
Free Cash Flow VolatilityVolatile and recently negative free cash flow reduces internal funding for commercialization and integration, increasing reliance on external financing. Persistent FCF weakness can constrain strategic flexibility, raise refinancing risk, and magnify the impact of adverse procedure volumes or working‑capital swings over a multi‑quarter horizon.
Elevated Post‑Acquisition LeverageMaterial borrowing to fund Endospan raises leverage and interest and refinancing exposure. Higher net debt reduces financial flexibility for organic investment or M&A, increases sensitivity to cash‑flow variability, and can pressure credit metrics if FCF does not normalize as acquisitions integrate and expected synergies are realized.
Margin Pressure From Rising OpEx And AmortizationGrowing SG&A, stock‑based comp, R&D and amortization from acquisitions compress operating leverage, making margin expansion harder despite revenue growth. If these elevated expense bases persist, they could limit conversion of top‑line gains to durable profits and delay cash‑flow normalization post‑integration.
AORT FAQ
What was Artivion Inc.’s price range in the past 12 months?
Artivion Inc. lowest stock price was $19.16 and its highest was $48.25 in the past 12 months.
What is Artivion Inc.’s market cap?
Artivion Inc.’s market cap is $1.41B.
When is Artivion Inc.’s upcoming earnings report date?
Artivion Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 68 days.
How were Artivion Inc.’s earnings last quarter?
Artivion Inc. released its earnings results on Aug 06, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of $0.002 by -$0.282.
Is Artivion Inc. overvalued?
According to Wall Street analysts Artivion Inc.’s price is currently Undervalued.
Does Artivion Inc. pay dividends?
Artivion Inc. pays a Quarterly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Artivion Inc. dividends here
What is Artivion Inc.’s EPS estimate?
Artivion Inc.’s EPS estimate is -0.06.
How many shares outstanding does Artivion Inc. have?
Artivion Inc. has 48,756,220 shares outstanding.
What happened to Artivion Inc.’s price movement after its last earnings report?
Artivion Inc. reported an EPS of -$0.28 in its last earnings report, missing expectations of $0.002. Following the earnings report the stock price went up 2.07%.
Which hedge fund is a major shareholder of Artivion Inc.?
Currently, no hedge funds are holding shares in AORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artivion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.87 (65.61% Upside)
$41.87 (65.61% Upside)
Blogger Sentiment
Bullish
AORT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 598.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
27.86%
Trailing 12-Months
Company Description
Artivion Inc.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
AORT Company Deck
AORT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive strategic and commercial story with multiple high‑impact milestones (AMDS PMA approval, Endospan/NEXUS acquisition, accelerating stent graft and On‑X growth) and reiterated full‑year guidance. These positives were offset by near‑term financial and operational headwinds: margin pressure, higher operating costs and amortization from the acquisition, negative free cash flow in the quarter driven by acquisition‑related cash outflows, and elevated leverage. Management emphasized that several lowlights are investment‑ or timing‑related and positioned as temporary as the business scales and NEXUS/AMDS commercialization progresses.View all AORT earnings summariesAORT Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$41.87
▲(65.61% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
5.11% Insiders
33.31% Mutual Funds
31.62% Other Institutional Investors
8.91% Public Companies and
Individual Investors








